

Ludwig Presence at 2019 ASCO Annual Meeting

Ludwig Scientist(s)	Affiliation(s)	Session Time	Presentation Time	Location	Session Type	Session Track	Session Title	Presentation/Abstract Title
Friday, May 31								
Bianca Santomaso	Ludwig MSK	4:30 - 5:45 PM	4:50 - 5:10 PM	E451	Education Session	Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft Care Delivery and Practice Management Disparities/Health Equity Immunotherapy Symptoms and Survivorship Value	The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden	Neurotoxicity From CAR T-Cell Therapy: Why It Happens, How to Manage It, and Who Is at Risk?
Saturday, June 1								
George D. Demetri	Ludwig Harvard	8:00 - 11:00 AM	N/A	E450	Oral Abstract Session	Sarcoma	Sarcoma	Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950)
George D. Demetri	Ludwig Harvard	8:00 - 11:00 AM	N/A	Hall A, Poster Board #342	Poster Session	Sarcoma	Sarcoma	Exploration of tumor genetic alterations and associations with clinical outcomes: Retrospective genomic analysis of archived liposarcoma (LPS) and leiomyosarcoma (LMS) samples from phase III trial of trabectedin (T) versus dacarbazine (D)
Suman Paul*, Jacqueline Douglass, Emily Han-Chung Hsue, Michael Hwang, Brian Mog, Nickolas Papadopoulos, Kenneth W. Kinzler, Alexander Pearlman, Bert Vogelstein, Shubin Zhou**	Ludwig Johns Hopkins	8:00 - 11:00 AM	N/A	Hall A, Poster Board #168	Poster Session	Developmental Immunotherapy and Tumor Immunobiology	Developmental Immunotherapy and Tumor Immunobiology	Targeting MHC-linked wild type p53 with TCR mimic single chain diabody for cancer immunotherapy
Jedd D. Wolchok	Ludwig MSK	8:00 - 9:30 AM	8:00 - 9:30 AM	Hall D1	Clinical Science Symposium	Melanoma/Skin Cancers	Melanoma/Skin Cancers	Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition
Dimitriy Zamarin**	Ludwig MSK	8:00 - 11:00 AM	N/A	Hall A, Poster Board #259	Poster Session	Developmental Immunotherapy and Tumor Immunobiology	Developmental Immunotherapy and Tumor Immunobiology	Response to immune checkpoint inhibition and survival in BRCA-associated recurrent ovarian cancer
Jedd D. Wolchok	Ludwig MSK	8:00 - 11:00 AM	1:15 - 2:45 PM	Hall A, Poster Board #156 + Hall D1	Poster Session and Poster Discussion Session	Developmental Immunotherapy and Tumor Immunobiology	Developmental Immunotherapy and Tumor Immunobiology	Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial
Gareth P Bond	Ludwig Oxford	8:00 - 11:00 AM	N/A	Hall A, Poster Board #138b	Poster Session	Developmental Therapeutics and Tumor Biology (Nonimmuno)	Developmental Therapeutics and Tumor Biology (Nonimmuno)	A first-in-human study of, NUC-7738, a 3'dA phosphoramidate, in patients with advanced solid tumors or lymphoma (NuTide 701)
Ash A. Alizadeh, Maximilian Diehn**	Ludwig Stanford	8:00 - 11:00 AM	N/A	Hall A, Poster Board: #191	Poster Session	Developmental Immunotherapy and Tumor Immunobiology	Developmental Immunotherapy and Tumor Immunobiology	ctDNA analysis for personalization of consolidation immunotherapy in localized non-small cell lung cancer
George Coukos	Ludwig Lausanne	1:15 - 4:15 PM	N/A	Hall A, Poster Board #49	Poster Session	Head and Neck Cancer	Head and Neck Cancer	Predictive biomarkers for response to nivolumab in head and neck squamous cell carcinoma (HNSCC)
Sylvie Rusakiewicz	Ludwig Lausanne	1:15 - 4:15 PM	N/A	Hall A, Poster Board #49	Poster Session	Head and Neck Cancer	Head and Neck Cancer	Predictive biomarkers for response to nivolumab in head and neck squamous cell carcinoma (HNSCC)
Dimitriy Zamarin	Ludwig MSK	1:15 - 4:15 PM	N/A	Hall A, Poster Board #405	Poster Session	Gynecologic Cancer	Gynecologic Cancer	A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma
Maximilian Diehn	Ludwig Stanford	1:15 - 4:15 PM	2:39 - 2:51 PM	Hall D2	Oral Abstract Session	Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers	Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers	Neoadjuvant Immunotherapy: Why, How, When?
George D. Demetri	Ludwig Harvard	3:00 - 4:30 PM	N/A	S404	Poster Session Discussion	Sarcoma	Sarcoma	Exploration of tumor genetic alterations and associations with clinical outcomes: Retrospective genomic analysis of archived liposarcoma (LPS) and leiomyosarcoma (LMS) samples from phase III trial of trabectedin (T) versus dacarbazine (D)
Dimitriy Zamarin	Ludwig MSK	4:30 - 6:00 PM	N/A	S406	Poster Discussion Session	Gynecologic Cancer	Gynecologic Cancer	Chair
David Scadden	Ludwig Harvard	4:45 - 6:00 PM	5:05 - 5:25 PM	S100bc	Special Sessions	ASCO Book Club	ASCO Book Club: Cancerland: A Medical Memoir by David Scadden, MD	Cancerland: A Medical Memoir
Rakesh Jain	Ludwig Harvard	4:45 - 6:00 PM	4:45 - 5:00 PM	Hall D2	Education Session	Developmental Immunotherapy and Tumor Immunobiology	Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies	Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Bench to Bedside (Chair)
Sunday, June 2								
Muriel Laine*, Ya-Fang Chang, Geoffrey Greene, Marianne Greene	Ludwig Chicago	8:00 - 11:00 AM	N/A	Hall A, Poster Board: #137	Poster Session	Breast Cancer—Metastatic	Breast Cancer—Metastatic	Lasofixifene as a potential treatment for ER+ metastatic breast cancer
Steven J. Chmura*	Ludwig Chicago	8:00 - 11:00 AM	N/A	Hall A, Poster Board: #189b	Poster Session	Breast Cancer—Metastatic	Breast Cancer—Metastatic	NRG-BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer (NCT02364557)
Andrew J. Park, Paul Schwarzenberger, Toni Ricciardi, Mary J. Macri, Aileen Ryan, Ralph R. Venhaus**	Ludwig Clinical Trials Management	8:00 - 11:00 AM	N/A	Hall A, Poster Board: #221	Poster Session	Central Nervous System Tumors	Central Nervous System Tumors	Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM)
Sadna Budhu, Taha Merghoub, George Pitas, Phillip Wong	Ludwig MSK	8:00 - 11:00 AM	N/A	Hall A, Poster Board: #84	Poster Session	Cancer—Breast Cancer—Local/Regional/Adjuvant	Cancer—Breast Cancer—Local/Regional/Adjuvant	Preoperative checkpoint inhibition (CPI) and cryoablation (Cryo) in women with early-stage breast cancer (ESBC)
Monday, June 3								
George Demetri*	Ludwig Harvard	8:00 - 11:00 AM	9:12 - 9:24 AM	S406	Oral Abstract Session	Developmental Therapeutics and Tumor Biology (Nonimmuno)	Developmental Therapeutics and Tumor Biology (Nonimmuno)	First-in-human phase 1 study of ABBV-085, an antibody-drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors

Joshua Cohen, Nickolas Papadopoulos, Kenneth W. Kinzler, Bert Vogelstein	Ludwig Johns Hopkins	8:00 - 11:00 AM	11:30 AM - 1:00 PM	Hall A, Poster Board: #10 + Arie Crown Theater	Poster Session and Poster Discussion Session	Gastrointestinal (Colorectal) Cancer	Gastrointestinal (Colorectal) Cancer	A pooled analysis of multicenter cohort studies of post-surgery circulating tumor DNA (ctDNA) in early stage colorectal cancer (CRC).
Jorge Carrasquillo	Ludwig MSK	8:00 - 11:00 AM	N/A	Hall A, Poster Board #255a	Poster Session	Gastrointestinal (Noncolorectal) Cancer	Gastrointestinal (Noncolorectal) Cancer	Phase 2 trial of Lu-177-DOTATATE in inoperable pheochromocytoma/ paraganglioma
Dimitriy Zamarin	Ludwig MSK	8:00 - 11:00 AM	N/A	Hall A, Poster Board #217	Poster Session	Gastrointestinal (Noncolorectal) Cancer	Gastrointestinal (Noncolorectal) Cancer	Efficacy and safety of pembrolizumab in patients with advanced adrenocortical carcinoma
Alexander M. Lesokhin	Ludwig MSK	8:00 - 11:00 AM	N/A	Hall A, Poster Board: #377	Poster Session	Hematologic Malignancies—Plasma Cell Dyscrasia	Hematologic Malignancies—Plasma Cell Dyscrasia	Ixazomib and dexamethasone in high risk smoldering multiple myeloma: A clinical and correlative pilot study
Danny Khalil	Ludwig MSK	8:00 - 11:00 AM	N/A	Hall A, Poster Board: #237	Poster Session	Gastrointestinal (Noncolorectal) Cancer	Gastrointestinal (Noncolorectal) Cancer	Homologous recombination deficiency (HRD): A biomarker for first-line (1L) platinum in advanced pancreatic ductal adenocarcinoma (PDAC)
Crystal Mackall	Ludwig Stanford	8:00 - 11:00 AM	N/A	Hall A, Poster Board: #306	Poster Session	Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia	Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia	Monitoring ctDNA in r/r DLBCL patients following the CAR T-cell therapy axicabtagene ciloleucel: Day 28 landmark analysis
Jedd D. Wolchok	Ludwig MSK	9:45 - 11:00 AM	N/A	E350	Education Session	Professional Development	Tips for Successful COI Disclosure	Panelist
Kornelia Polyak	Ludwig Harvard	9:45 AM - 12:45 PM	N/A	Hall D2	Oral Abstract Session	Breast Cancer—Local/Regional/Adjuvant	Breast Cancer—Local/Regional/Adjuvant	HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial
F. Stephen Hodi, Benjamin Izar	Ludwig Harvard	1:15 - 4:15 PM	N/A	Hall A, Poster Board #127	Poster Session	Melanoma/Skin Cancers	Melanoma/Skin Cancers	Characterization of the genetics of mucosal melanoma in patients treated with immunotherapy
Alexander M. Lesokhin, Jedd D. Wolchok, Margaret K. Callahan, Michael A. Postow	Ludwig MSK	1:15 - 4:15 PM	N/A	Hall A, Poster Board: #104	Poster Session	Melanoma/Skin Cancers	Melanoma/Skin Cancers	Long-term follow-up of CA209-004: A phase I dose-escalation study of combined nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma
Margaret K. Callahan, Jedd D. Wolchok, Michael A. Postow	Ludwig MSK	1:15 - 4:15 PM	4:30 - 6:00 PM	Hall A, Poster Board: #84 + E451	Poster Session and Poster Discussion Session	Melanoma/Skin Cancers	Melanoma/Skin Cancers	Responders to anti-PD1 therapy: Long-term outcomes and responses to retreatment in melanoma (mel)
Jedd D. Wolchok, Margaret K. Callahan, Michael A. Postow	Ludwig MSK	1:15 - 4:15 PM	N/A	Hall A, Poster Board: #110	Poster Session	Melanoma/Skin Cancers	Melanoma/Skin Cancers	Therapeutic implications of a novel driver classification system for cutaneous and unknown primary melanomas
Jedd D. Wolchok	Ludwig MSK	1:15 - 4:15 PM	N/A	Hall A, Poster Board: #122	Poster Session	Melanoma/Skin Cancers	Melanoma/Skin Cancers	Patient-reported quality of life (QoL) of advanced melanoma patients in a Phase 3 study of nivolumab (NIVO) with or without ipilimumab (IPI) versus IPI: CheckMate 067 4-year data
Taha Merghoub, Jedd D. Wolchok, Phillip Wong	Ludwig MSK	1:15 - 4:15 PM	N/A	Hall A, Poster Board: #385	Poster Session	Genitourinary (Nonprostate) Cancer	Genitourinary (Nonprostate) Cancer	A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC)
Michael A. Postow	Ludwig MSK	1:15 - 4:15 PM	N/A	Hall A, Poster Board: #168a	Poster Session	Melanoma/Skin Cancers	Melanoma/Skin Cancers	A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC-X Trial)
Steven M. Larson	Ludwig MSK	1:15 - 4:15 PM	N/A	S102	Oral Abstract Session	Central Nervous System Tumors	Central Nervous System Tumors	A phase I study of convection-enhanced delivery of 124I-8H9 radio-labeled monoclonal antibody in children with diffuse intrinsic pontine glioma: An update with dose-response assessment
Tuesday, June 4								
Nancy E. Davidson	Ludwig Board of Directors	7:30 - 9:15 AM	8:00 - 8:15 AM	Hall D1	Highlights of the Day Session	Special Sessions	Highlights of the Day Session III	Breast Cancer—Local/Regional/Adjuvant
Michael A. Postow	Ludwig MSK	9:45 AM - 12:45 PM	N/A	S406	Oral Abstract Session	Melanoma/Skin Cancers	Melanoma/Skin Cancers	Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204)
Publication-only Abstracts								
Wenxin Zheng	Ludwig Harvard	N/A	N/A	N/A	Publication Only	Gynecologic Cancer	Gynecologic Cancer	Significance of degree of destructive stromal invasion in early stage endocervical adenocarcinoma
George Demetri*, Ziming Du, Sandro Santagata	Ludwig Harvard	N/A	N/A	N/A	Publication Only	Sarcoma	Sarcoma	Molecular characterization and management of secondary resistance to serial TRK inhibitors
Billel Gasmi	Ludwig MSK	N/A	N/A	N/A	Publication Only	Developmental Immunotherapy and Tumor Immunobiology	Developmental Immunotherapy and Tumor Immunobiology	Utilization of novel highly multiplexed immunofluorescence microscopy technology to understand immunological tumor microenvironments in small cell lung carcinoma patients receiving combination PD-L1 and PARP inhibition therapy.
Jedd D. Wolchok, Michael A. Postow	Ludwig MSK	N/A	N/A	N/A	Publication Only	Symptoms and Survivorship	Symptoms and Survivorship	Long-term symptom burden and quality of life in metastatic melanoma patients treated with checkpoint inhibitors
Alexander M. Lesokhin	Ludwig MSK	N/A	N/A	N/A	Publication Only	Hematologic Malignancies—Plasma Cell Dyscrasia	Hematologic Malignancies—Plasma Cell Dyscrasia	Using MALDI-TOF mass spectrometry for tracking of minimal residual disease in peripheral blood from patients with multiple myeloma
Margaret K. Callahan	Ludwig MSK	N/A	N/A	N/A	Publication Only	Genitourinary (Nonprostate) Cancer	Genitourinary (Nonprostate) Cancer	Pretreatment eosinophil counts (PEC) in metastatic urothelial carcinoma (mUC) treated with anti-PD1/PD-L1 checkpoint inhibitors (CPI)
Steven M. Larson	Ludwig MSK	N/A	N/A	N/A	Publication Only	Central Nervous System Tumors	Central Nervous System Tumors	Intraventricular radioimmunotherapy targeting B7H3 for CNS malignancies